This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-09. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In 2024, Israel also placed sanctions on the Houthis. In September 2026, the G7 foreign ministers issued a joint statement condemning Houthi attacks on Saudi Arabia and calling on Iran to end its support for the Houthis.
In April 2021 Noakes pleaded guilty in France to manufacturing and selling fake medicinal products and cosmetics by Internet and sentenced to 4 years of jail. A 2019 Business Insider report detailed the activities of Amanda Mary Jewell, who sold GcMAF for years as an unlicensed cure for several medical conditions, including cancer and autism. Jewell is not a medical doctor.
== Mechanism of action == β-Endorphin acts as an agonist that binds to various types of G protein–coupled receptors (GPCRs), most notably to the mu and kappa opioid receptors. Binding to these receptors prevents the release of Substance P in the case of the peripheral nervous system, and the inhibitory neurotransmitter, GABA, in the central nervous system The receptors are responsible for supra-spinal analgesia. Radiotracer studies show that circulating β-endorphin is not transported across the blood–brain barrier and is rapidly degraded by endothelial peptidases.
Cold boxes are typically used to carry vaccines around the area. It is a self-supporting container with insulation and ice-packs surrounding the interior to keep vaccines at low temperatures. Unlike the refrigerator, the cold box has limited time to maintain temperatures below +10 °C, normally 48–96 hours. It comes in many different types and shapes, and this storage is very useful for the transportation of vaccines in or out of the health facility.
According to the Australian Forest and Wood Products Research and Development Corporation (FWPRDC), green sawn hardwood, which is sold at about $350 per cubic metre or less, increases in value to $2,000 per cubic metre or more with drying and processing. However, currently used conventional drying processes often result in significant quality problems from cracks, both externally and internally, reducing the value of the product. For example, in Queensland (Anon, 1997), on the assumption that 10% of the dried softwood is devalued by $200 per cubic metre because of drying defects, saw millers are losing about $5 million a year. In Australia, the loss could be $40 million a year for softwood and an equal or higher amount for hardwood. Thus, proper drying under controlled conditions prior to use is of great importance in timber use, in countries where climatic conditions vary considerably at different times of the year. Drying, if carried out promptly after felling of trees, also protects timber against primary decay, fungal stain and attack by certain kinds of insects. Organisms, which cause decay and stain, generally cannot thrive in timber with a moisture content below 20%. Several, though not all, insect pests can live only in green timber. In addition to the above advantages of drying timber, the following points are also significant:
Sources: en.wikipedia.org
"That way," Castro recounted on another occasion, "while the South African troops were being bled slowly dry in Cuito Cuanavale, down in the southwest...40,000 Cuban soldiers...backed by about 600 tanks, hundreds of artillery pieces, 1,000 anti-aircraft weapons, and the daring MiG-23 units that took over the skies, advanced towards the Namibian border, ready to sweep away the South African forces". As the Cuban brigades advanced, they accumulated thousands of PLAN insurgents, who departed their bases to join the offensive. The presence of so many Cuban troops effectively resuscitated PLAN's sagging fortunes, as it curtailed new South African military initiatives against the insurgents not only in Angola but South West Africa as well. Firstly, the region being occupied by the Cubans just north of the border was the same territory the SADF had monitored and patrolled for almost a decade in order to prevent PLAN infiltration into Ovamboland. Secondly, all South African units near the border had ceased routine counter-insurgency operations while they were being mobilised to resist a potential Cuban invasion. Matters were complicated further when the Cubans formed three joint battalions with PLAN fighters, each with its own artillery and armoured contingents. Due to the integration of the insurgents with Cuban personnel at the battalion level, South African patrols found it impossible to engage PLAN in Angola without risking a much larger confrontation involving aggressive and well-armed Cuban troops.
One of the most acutely toxic indoor air contaminants is carbon monoxide (CO), a colorless and odorless gas that is a by-product of incomplete combustion. Carbon monoxide may be emitted from tobacco smoke and generated from malfunctioning fuel burning stoves (wood, kerosene, natural gas, propane) and fuel burning heating systems (wood, oil, natural gas) and from blocked flues connected to these appliances. In developed countries the main sources of indoor CO emission come from cooking and heating devices that burn fossil fuels and are faulty, incorrectly installed or poorly maintained. Appliance malfunction may be due to faulty installation or lack of maintenance and proper use. In low- and middle-income countries the most common sources of CO in homes are burning biomass fuels and cigarette smoke. Health effects of CO poisoning may be acute or chronic and can occur unintentionally or intentionally (self-harm). By depriving the brain of oxygen, acute exposure to carbon monoxide may have effects on the neurological system (headache, nausea, dizziness, alteration in consciousness and subjective weakness), the cardiovascular and respiratory systems (myocardial infarction, shortness of breath, or rapid breathing, respiratory failure). Acute exposure can also lead to long-term neurological effects such as cognitive and behavioral changes. Severe CO poisoning may lead to unconsciousness, coma and death. Chronic exposure to low concentrations of carbon monoxide may lead to lethargy, headaches, nausea, flu-like symptoms and neuropsychological and cardiovascular issues.
Spark ionization (also known as spark source ionization) is a method used to produce gas phase ions from a solid sample. The prepared solid sample is vaporized and partially ionized by an intermittent discharge or spark. This technique is primarily used in the field of mass spectrometry. When incorporated with a mass spectrometer the complete instrument is referred to as a spark ionization mass spectrometer or as a spark source mass spectrometer (SSMS).
=== Casting === Merle Dandridge reprised her role as Alyx for initial recording sessions in March 2019, but after playtests indicated that Alyx needed a younger voice, Ozioma Akagha was cast in September 2019. Akagha avoided using irritation in her performance, as "you don't want someone in your head that sounds irritated with you". Additional actors include James Moses Black as Eli, replacing Robert Guillaume, who died in 2017, and Rhys Darby as Russell, who added comedic elements. Returning actors include Tony Todd as the alien Vortigaunts, Mike Shapiro as the G-Man, and Ellen McLain as the voice of the Combine broadcasts. Shapiro recorded his lines in one 20-minute take, with pickups in 2019. Cissy Jones (Olga) and Rich Sommer (Larry, Russell's drone, and Combine Soldiers) were cast at the suggestion of the writer Sean Vanaman, who had worked with them on Campo Santo's Firewatch (2016).
Since ABA dissipates slowly from the tissues and its effects take time to be offset by other plant hormones, there is a delay in physiological pathways that provides some protection from premature growth. Abscisic acid accumulates within seeds during fruit maturation, preventing seed germination within the fruit or before winter. Abscisic acid's effects are degraded within plant tissues during cold temperatures or by its removal by water washing in and out of the tissues, releasing the seeds and buds from dormancy. ABA exists in all parts of the plant, and its concentration within any tissue seems to mediate its effects and function as a hormone; its degradation, or more properly catabolism, within the plant affects metabolic reactions and cellular growth and production of other hormones. Plants start life as a seed with high ABA levels. Just before the seed germinates, ABA levels decrease; during germination and early growth of the seedling, ABA levels decrease even more. As plants begin to produce shoots with fully functional leaves, ABA levels begin to increase again, slowing down cellular growth in more "mature" areas of the plant. Stress from water or predation affects ABA production and catabolism rates, mediating another cascade of effects that trigger specific responses from targeted cells. Scientists are still piecing together the complex interactions and effects of this and other phytohormones. In plants under water stress, ABA plays a role in closing the stomata.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.